Working… Menu
Trial record 35 of 37 for:    Recruiting, Not yet recruiting, Available Studies | Receptor tyrosine kinase

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT03909334
Recruitment Status : Recruiting
First Posted : April 10, 2019
Last Update Posted : October 15, 2019
M.D. Anderson Cancer Center
Eli Lilly and Company
Information provided by (Responsible Party):
Xiuning Le, Hoosier Cancer Research Network

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : June 2024